Eagle Pharmaceuticals, Inc. today announced that its marketing partner, SymBio Pharmaceuticals Limited, has received regulatory approval for TREAKISYM ready-to-dilute liquid formulation from the ...

Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM ® Rapid Infusion Liquid Bendamustine Formulation March 30, 2020 06:50 AM ...

TOKYO--(BUSINESS WIRE)--SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") (JASDAQ: 4582) announced today that it has initiated a Phase 1 study in Japan for oral TREAKISYM ® in ...

Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit Royalties “Furthermore, SymBio’s success in transitioning ...

SymBio Pharmaceuticals Limited. and Eisai Co., Ltd. announced that the companies have concluded the license agreement for the co-development and commercialization of bendamustine hydrochloride in ...